SkyQuest Technology Group recently introduced Liquid Biopsy Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Liquid Biopsy Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Global Liquid Biopsy Market size was valued at USD 7.6 billion in 2023 and is poised to grow from USD 8.75 billion in 2024 to USD 26.95 billion by 2032, growing at a CAGR of 15.1% during the forecast period (2025-2032).
One of the most advanced technologies related to genetic alterations and used for the detection of a tumor is liquid biopsy. It has been used in the stratification of the tumor, thereby offering targeted therapy to the cancer. For instance, the FDA approved, in January 2023, the liquid biopsy assay Guardant360 CDx by Guardant Health as a companion diagnostic to diagnose ESR1 mutant breast cancer. Recent inventions, progressions, and expansion in this sector boost liquid biopsy and foster market growth.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/liquid-biopsy-market
Another critical growth opportunity for the global liquid biopsy market is provided by Multi Cancer Early Detection (MCED). The MCED market is an emerging sector of interest for the diagnostics industry as it allows the early detection of cancer and, consequently, the early treatment of such patients by saving time and minimizing the risk of such invasive medical surgical procedures. Some disadvantages of single cancer tests include high false-positive rates and optimized sensitivity.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Liquid Biopsy Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Product
Assay Kits, Instruments, Services
Circulating Biomarker
Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA, Extracellular Vesicles, Other Circulating Biomarkers
Technology
Multi-Gene Parallel Analysis Using NGS, Single-Gene Analysis Using PCR
Application
Cancer Applications (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Cancers), Non-Cancer Applications (Non-Invasive Prenatal Testing, Organ Transplantation, Infectious Disease Testing)
Clinical Application
Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring
Sample Type
Blood Samples, Other Sample Types
End User
Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers, Other End Users
Liquid Biopsy Market – Regional Analysis:
– Liquid Biopsy North America Market includes (Canada, Mexico, USA)
– Liquid Biopsy Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Liquid Biopsy Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Liquid Biopsy South America Market includes (Brazil, Argentina)
– Liquid Biopsy Oceania Market (Australia & New Zealand)
Top Market Players in Liquid Biopsy Market are:
F. Hoffmann-La Roche Ltd (Switzerland)
Thermo Fisher Scientific Inc. (US)
Illumina, Inc. (US)
Guardant Health, Inc. (US)
Biocept, Inc. (US)
Sysmex Corporation (Japan)
Natera, Inc. (US)
Biocartis Group NV (Belgium)
Bio-Rad Laboratories, Inc. (US)
OncoCyte Corporation (US)
Adaptive Biotechnologies Corporation (US)
Angle PLC (United Kingdom)
Epic Sciences, Inc. (US)
Neogenomics Laboratories (US)
CellMax Life (US)
Menarini-Silicon Biosystems (Italy)
Lunglife AI Inc. (US)
Recent Developments in Liquid Biopsy Market:
In June 2022, F. Hoffmann-La Roche Ltd. collaborated with the Lung Cancer Research Foundation (LCRF) and Lung Cancer Mutation Consortium (LCMC) to participate in the LCMC 4th screening trial to evaluate actionable drivers in early-stage lung cancer for targeted therapy options in patients.
In May 2022, Guardant Health, Inc. announced that its blood-sample-based cancer testing services are now available at VHIO’s liquid biopsy testing facility in Barcelona, Europe.
In April 2022, Stilla Technologies and Promega Corporation have announced a strategic partnership to offer a comprehensive digital PCR workflow solution for a broad portfolio of applications in cancer research, including liquid biopsy, sentinel pathogen testing, among others.
Also Read –
https://www.openpr.com/news/3948457/coating-additives-market-future-industry-shifts-and-long-term
https://pando.life/article/818524
Forward-Looking Insights
The Liquid Biopsy Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
